Project in collaboration with IDIBELL / Hospital Universitariio de Bellvitge (Barcelona) – 9/17/20, num 276/20
We are conducting a hospital clinical trial to measure the infectivity of the SARS-CoV-2 virus and slow down the replication of the virus in host cells.
We are measuring the degree of participation of certain enzymatic biomarkers in the anchorage and penetration of the virus in the host cell
We will offer a scoring of the vulnerability of each individual to infection in the face of virus exposure.
We have drugs candidates to modify the expresion of biomarkers involved in the infection
The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and l’Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council.
IDIBELL research is focused in cancer, neuroscience, translational medicine and regenerative medicine. Research, innovation and society are the axes on which researchers work every day with the goal of improving the quality of life of citizens.
This content is restricted to Investors. If you are an existing investor, please log in.